University of Newcastle, Newcastle, NSW, Australia.
Integr Cancer Ther. 2020 Jan-Dec;19:1534735420975861. doi: 10.1177/1534735420975861.
We reviewed the research into the mechanisms of growth of triple negative breast cancer (TNBC) based on laboratory pre-clinical studies that have shaped understanding of the disease over the past decade. In response to these findings, we propose an approach to potentially prevent cancer metabolic adaptation and recurrence. This paper collates pre-clinical results, first to determine the tumor's mechanisms of growth and then to source natural substances that could potentially suppress those mechanisms. The results from in vivo and in vitro studies of TNBC were combined first to select 10 primary mechanisms (Hypoxia-inducible factor 1α, Hedgehog, MAPK, MTAP, NF-κ B, Notch, P13K, STAT3, and Wnt signaling pathways plus and gene expression) that promote TNBC growth, and second to propose a treatment array of 21 natural compounds that suppress laboratory models of TNBC via these mechanisms. We included mutations in the review process, but only pathways with the most preclinical studies utilizing natural products were included. Then we outlined potential biomarkers to assess the changes in the micro-environment and monitor biochemical pathway suppression. This suppression-centric aim targets these mechanisms of growth with the goal of potentially halting tumor growth and preventing cancer cell metabolic adaptation. We chose TNBC to demonstrate this 5-step strategy of supplementary therapy, which may be replicated for other tumor types.
我们回顾了基于过去十年中对该疾病形成认识的实验室临床前研究的三阴性乳腺癌 (TNBC) 生长机制的研究。针对这些发现,我们提出了一种可能预防癌症代谢适应和复发的方法。本文汇集了临床前研究结果,首先确定肿瘤的生长机制,然后寻找可能抑制这些机制的天然物质。首先,将 TNBC 的体内和体外研究结果结合起来,选择了 10 个主要促进 TNBC 生长的机制(缺氧诱导因子 1α、Hedgehog、MAPK、MTAP、NF-κB、Notch、PI3K、STAT3 和 Wnt 信号通路以及 和 基因表达),其次提出了一种治疗数组,其中包括 21 种天然化合物,通过这些机制抑制 TNBC 的实验室模型。我们在审查过程中包括了 突变,但仅包括利用天然产物进行了最多临床前研究的途径。然后,我们概述了潜在的生物标志物,以评估微环境的变化并监测生化途径的抑制。这种以抑制为中心的目标针对这些生长机制,旨在潜在地阻止肿瘤生长并防止癌细胞代谢适应。我们选择 TNBC 来展示这种辅助治疗的 5 步策略,该策略可能适用于其他肿瘤类型。